News | December 05, 2021
Eris signs JV with MJ Biopharm to supply insulin in India
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
The fund aims at investing in companies that extends human healthspan
The hospital is scheduled to open in 2024 with a bed capacity of 225
SPARC will pay Biomodifying a percentage of payments received for sublicenses of the licensed IP
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
The first hospital in Kharadi launched three years ago has made a significant difference to women and children's health
Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million
Union Minister Dr Jitendra Singh said a large number of Covid-19 bio-repositories and samples were made available to academia and industry
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Subscribe To Our Newsletter & Stay Updated
